Home HOME Neoplasma 2013 Neoplasma Vol.60, No.5, p.511-515, 2013

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.60, No.5, p.511-515, 2013

Title: MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration
Author: H. LI, J. ZHAO, J. W. ZHANG, Q. Y. HUANG, J. Z. HUANG, L. S. CHI, H. J. TANG, G. Q. LIU, D. J. ZHU, W. M. MA

Abstract: Aberrantly expressed microRNAs (miRNAs) are frequently correlated with a  variety of human cancers, including clear cell renal cell carcinoma (ccRCC). In this study, we determined the expression patterns of miR-217 in ccRCC, and tested its effect on cancer cell proliferation and migration. The expression levels of miR-217 were determined in 54 ccRCC samples using Real-Time qPCR. 786-O and ACHN cells were transfected with miR-217 mimics or miRNA mimics control. Cell proliferation and migration were evaluated by MTT assay and scratch-wound assay, respectively. We found that miR-217 was down-regulated in ccRCC compared to paired normal tissue. Lower miR-217 expression levels were associated with higher tumor grade and stage. All patients with high miR-217 expression survived 5 years, while with low miR-217 expression, only 40% survived. Cell proliferation inhibition and decreased motility were observed in cells transfected with the miR-217 mimics. In conclusion, miR-217 plays a  tumor suppressor role in ccRCC.

Keywords: miR-217, clear cell renal cell carcinoma, survival, proliferation, migration
Published online: 24-Jun-2013
Year: 2013, Volume: 60, Issue: 5 Page From: 511, Page To: 515

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.